{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 44,
  "pageCount": 58,
  "prevPage": 43,
  "nextPage": 45,
  "slideType": "client_example",
  "function": "illustrate_case",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide highlights the trend of international pharma companies licensing innovative assets from Chinese biotech firms.",
  "elementsJson": [
    "data_table",
    "logo_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/44",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-44",
  "components": [
    {
      "bbox": {
        "h": 0.018,
        "w": 0.169,
        "x": 0.831,
        "y": 0.00182
      },
      "kind": "callout",
      "text": "NON-EXHAUSTIVE",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86190c4d-5993-49df-b792-871383cdd68b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Deal size (USD Mn): 2,940",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-5ccd2d1ed76a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.335,
        "x": 0.036,
        "y": 0.891
      },
      "kind": "source-note",
      "text": "Note: *Including upfront and milestone payments\nSource: Company websites, DXY, Cortellis Deal Intelligence, L.E.K. research and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87a93335-d91d-430d-a27f-2497b7105bc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.695,
        "w": 0.964,
        "x": 0.036,
        "y": 0.208
      },
      "kind": "table",
      "text": "Select China pharmaceuticals out-licensing examples (2020-22 Aug, not exclusive)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a31a6497-0efa-4c73-9e40-fd9b2bc8e698",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.735,
        "x": 0.036,
        "y": 0.105
      },
      "kind": "title",
      "text": "... among which leading international pharma are actively licensing in Chinese innovative assets",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9a38299-c786-4dcd-8302-2187561b394e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.248,
        "x": 0.036,
        "y": 0.035
      },
      "kind": "title",
      "text": "Evolution of MNC China R&D strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47a3b394-cad9-4dec-b07a-63fa92936333",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Deal size (USD Mn)",
      "numberRaw": "2,940",
      "numberKind": "plain",
      "actionTitle": "... among which leading international pharma are actively licensing in Chinese innovative assets",
      "calloutText": null,
      "numberScale": null,
      "numberValue": 2.94,
      "metricFamily": "market_size",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}